Sign In
Buy PASG
$5.97
+0.0750 (+1.27%)
At Close: Jun 03, 2026
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
07:00am, Monday, 20'th Apr 2026
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels
Analysts Set Passage Bio, Inc. (NASDAQ:PASG) PT at $42.67
02:52am, Thursday, 05'th Mar 2026
Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the four ratings firms that are currently covering the stock, MarketBeat Ra
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
07:00am, Tuesday, 03'rd Mar 2026
Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety
Passage Bio to Participate in Upcoming Investor Conferences
07:00am, Thursday, 19'th Feb 2026
PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67
02:54am, Sunday, 08'th Feb 2026
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four brokerages that are currently covering the stock, MarketBeat reports. One equitie
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $42.67
03:52am, Wednesday, 14'th Jan 2026
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been given an average rating of "Moderate Buy" by the four research firms that are currently covering the company, Marketbeat Ratings reports. On
Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)
02:00am, Saturday, 27'th Dec 2025
Passage Bio (NASDAQ: PASG - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two c
Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)
03:02am, Sunday, 07'th Dec 2025
Passage Bio (NASDAQ: PASG - Get Free Report) and PepGen (NASDAQ: PEPG - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based o
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67
03:28am, Tuesday, 25'th Nov 2025
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
04:15pm, Monday, 10'th Nov 2025
Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comp
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
07:00am, Wednesday, 05'th Nov 2025
PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,
Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference
07:00am, Tuesday, 14'th Oct 2025
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,
Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet
10:56am, Monday, 01'st Sep 2025
The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
07:00am, Thursday, 28'th Aug 2025
PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade
10:55am, Friday, 15'th Aug 2025
The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an
